VANCOUVER, BC, May 13, 2022
/CNW/ - Willow Biosciences Inc. ("Willow" or the
"Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce
the voting results from its annual general meeting of shareholders
held on May 13, 2022 (the
"Meeting"). A total of 42,387,564 common shares,
representing approximately 34.31% of the Company's issued and
outstanding shares were represented at the meeting.
The following nominees were elected as directors of Willow for
the ensuing year with the specific voting results being as
follows:
|
Votes For
|
Votes
Withheld
|
Director
|
#
|
%
|
#
|
%
|
Dr. Peter
Seufer-Wasserthal
|
36,177,987
|
99.18%
|
300,231
|
0.82%
|
Trevor
Peters
|
36,166,230
|
99.14%
|
311,988
|
0.86%
|
Dr. Fotis
Kalantzis
|
35,666,513
|
97.77%
|
811,705
|
2.23%
|
Donald
Archibald
|
36,092,217
|
98.94%
|
386,001
|
1.06%
|
Sadiq H.
Lalani
|
35,671,203
|
97.79%
|
807,015
|
2.21%
|
Al Foreman
|
35,867,631
|
98.33%
|
610,587
|
1.67%
|
Barbara
Munroe
|
36,160,678
|
99.13%
|
317,540
|
0.87%
|
In addition, shareholders approved the appointment of KPMG LLP
as the Company's auditor for the ensuing year (99.99% of the votes
cast being in favour). For complete voting results on all matters
approved at the Meeting, please see the Company's Report of Voting
Results dated May 13, 2022 available
on SEDAR at www.sedar.com.
About Willow Biosciences
Inc.
Willow is a leading biotechnology company that develops and
produces high-purity, plant derived ingredients for the personal
care, food and beverage, and pharmaceutical markets. Willow's
FutureGrown™ biotechnology platform allows large-scale production
of pure, consistent, and sustainable products to benefit our B2B
partners and their customers.
SOURCE Willow Biosciences Inc.